GE HealthCare stock heads into the open after a 0.5% slip
Published on 09/14/2026 at 06:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
GE HealthCare stock closed at USD 63.93 on the Nasdaq on September 11, 2026, losing 0.48% from the prior session per Nasdaq data reported by MarketBeat. The move came as the stock continued to trade within its recent range and lagged the performance of some former GE peers.
September 11, 2026 in numbers
GE HealthCare Technologies Inc. (ISIN US36266G1076, Nasdaq: GEHC) ended the September 11, 2026 session at USD 63.93 on the Nasdaq, down 0.48% on the day, with the closing price tied to regular trading hours at 4:00 p.m. Eastern according to data cited by MarketBeat. The stock's change reflected a modest decline as it continued to trade between its 12-month low of USD 58.75 and its 12-month high of USD 89.77, figures also highlighted in the September 13, 2026 update from MarketBeat. Per that same filing-based report, the shares opened that Friday session at USD 63.93, underscoring the narrow intraday range and a relatively steady tone despite the modest percentage loss.
Session trading volume on September 11, 2026 was consistent with recent levels, and the stock's closing performance slightly trailed broader equity benchmarks as the S&P 500 index also eased in the latest completed session. A valuation-focused note from GuruFocus on September 13, 2026 pointed out that GE HealthCare was trading around USD 63.93, which the service framed as roughly a 24.4% discount to its intrinsic value estimate of USD 84.51, giving investors additional context on the stock's position between its 12-month extremes. In relative terms, the stock's recent path has lagged the stronger gains seen at former GE affiliates such as GE Vernova and GE Aerospace, a contrast noted in a September 13, 2026 market report by Seeking Alpha.
Today’s outlook around potential deal news
Into today's session on September 14, 2026, attention around GE HealthCare is shaped by reports that the company is in advanced talks to acquire cancer-scan chemical maker Sofie Biosciences for approximately USD 1 billion, a strategic move detailed by Seeking Alpha on September 13, 2026 and echoed in a separate report from the Financial Times. These deal discussions add a corporate-action angle that could influence sentiment today as investors assess potential balance-sheet implications and growth prospects in diagnostics. Broader market conditions are also in focus, with economic and earnings calendars from Yahoo Finance signaling a busy macro backdrop this week that may affect rate-sensitive healthcare names alongside the wider S&P 500.
